The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis

Table 1 The expression of hTERT mRNA in 116 cases of gastric mucosas

groups	n	hTERT mRNA			positive (%)
		+	++	+++
CSG	30	0	0	0	0
CAG	27	10	0	0	37
AP	8	2	1	0	38
GU	9	3	0	0	33
GC	42	15	18	3	86

Table 2 T lymphocyte subsets and NK cells in different gastric disease (¯x ± s)

groups	n	CD3+ (%)	CD4+ (%)	CD8+ (%)	CD4+/CD8+	NK
NC	20	68.0 ± 2.0	39.9 ± 4.5	27.1 ± 4.5	1.4 ± 0.2	21.4 ± 3.7
CSG	30	61.6 ± 4.4a	35.9 ± 3.3a	26.7 ± 4.2	1.4 ± 0.1	20.1 ± 5.1
CAG	27	57.6 ± 3.1ac	33.5 ± 2.8ac	26.8 ± 2.8	1.2 ± 0.1bd	13.5 ± 3.4bd
GC	42	53.4 ± 10.6e	29.4 ± 7.6e	35.6 ± 8.6e	0.9 ± 0.4e	9.4 ± 4.4f

^aP < 0.05,

^bP < 0.01 vs NC;

^cP < 0.05

^dP < 0.01 vs CSG;

^eP < 0.05,

^fP < 0.01 vs CAG

Table 3 T lymphocyte subsets and NK cells in different stages of gastric cancer (¯x ± s)

groups	n	CD3+ (%)	CD4+ (%)	CD8+ (%)	CD4+/CD8+	NK
tumor gross type
early	8	57.5 ± 5.5	32.1 ± 9.1	28.2 ± 10.0	1.1 ± 0.6	8.7 ± 3.9
advanced	34	52.9 ± 9.8b	26.8 ± 6.0b	35.5 ± 8.1	0.8 ± 0.3a	9.6 ± 4.5
lymph node metastasis
without	13	57.3 ± 7.8	31.2 ± 7.4	32.4 ± 8.5	1.1 ± 0.4	9.7 ± 4.7
with	29	52.5 ± 10.1c	25.7 ± 5.8c	36.7 ± 8.1	0.7 ± 0.3c	9.2 ± 4.3

^aP < 0.05,

^bP < 0.01vs early-stage cancer;

^cP < 0.05 vs the cancer patients without lymph node metastasis